From the Cardiology Branch, National Heart, Lung, and Blood Institute
(N.D., D.M.G., A.A.Q.), Bethesda, Md, and Cardiology Division, Department of
Medicine, Jewish General Hospital, McGill University (J.G.D.), Montreal,
Quebec, Canada.
Correspondence to Jean G. Diodati, MD, Cardiology Division, Jewish General Hospital, 3755 Cote Ste-Catherine Rd, Suite E-206, Montreal, Quebec, Canada H3T 1E2. E-mail mc72{at}musica.mcgill.ca
Background—We investigated whether
luminal release of nitric oxide (NO) contributes to inhibition of
platelet activation and whether these effects are reduced in
patients with atherosclerosis.
Methods and Results—Femoral blood flow velocity and ex vivo whole
blood platelet aggregation by impedance aggregometry were measured
in femoral venous blood during femoral arterial infusion of
acetylcholine (ACh; 30 µg/min) in 30 patients, 19 of whom had
angiographic atherosclerosis. Measurements were
repeated with sodium nitroprusside (40 µg/min),
L-arginine (160 µmol/min), and
NG-monomethyl-L-arginine
(L-NMMA; 16 µmol/min). There was significant inhibition of
collagen-induced platelet aggregation with ACh (45±9.5% lower,
P<0.001), and this inhibition was greater in patients
without atherosclerosis (68.7±10.4% reduction) than
in those with atherosclerosis (32.5±8.1%,
P=0.04). The magnitude of inhibition correlated with
vasodilation with ACh, indicating an association between the smooth
muscle and antiplatelet effects of
endothelium-dependent stimulation. Neither L-NMMA nor
sodium nitroprusside altered platelet aggregation.
L-Arginine inhibited platelet aggregation equally in
vitro (34±8% reduction, P<0.01) and in vivo (37±13%
reduction, P<0.01).
Conclusions—Stimulation of NO release into the vascular lumen
with ACh inhibits platelet aggregation, an effect that is
attenuated in patients with atherosclerosis and
endothelial dysfunction. Basal NO release does not
appear to contribute to platelet passivation in vivo.
L-Arginine inhibited platelet aggregation by its direct
action on platelets. These findings provide a
pathophysiological basis for the observed increase
in thrombotic events in atherosclerosis. Use of
L-arginine and other strategies to improve
endothelial NO activity may impact favorably on
thrombotic events in atherosclerosis.
© 1998 American Heart Association, Inc.
Clinical Investigation and Reports
Effect of Atherosclerosis on Endothelium-Dependent Inhibition of Platelet Activation in Humans
Key Words: endothelium • atherosclerosis • blood flow • nitric oxide • platelets
This article has been cited by other articles:
 |
|
 |
|
  K. Ramasubbu, J. Estep, D. L. White, A. Deswal, and D. L. Mann Experimental and clinical basis for the use of statins in patients with ischemic and nonischemic cardiomyopathy. J. Am. Coll. Cardiol., January 29, 2008; 51(4): 415 - 426. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Bugiardini and C. N. Bairey Merz Angina With "Normal" Coronary Arteries: A Changing Philosophy JAMA, January 26, 2005; 293(4): 477 - 484. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. P. Faxon, V. Fuster, P. Libby, J. A. Beckman, W. R. Hiatt, R. W. Thompson, J. N. Topper, B. H. Annex, J. H. Rundback, R. P. Fabunmi, et al. Atherosclerotic Vascular Disease Conference: Writing Group III: Pathophysiology Circulation, June 1, 2004; 109(21): 2617 - 2625. [Full Text] [PDF]
|
|
|
|
|
|
R. Bugiardini, O. Manfrini, C. Pizzi, F. Fontana, and G. Morgagni Endothelial Function Predicts Future Development of Coronary Artery Disease: A Study of Women With Chest Pain and Normal Coronary Angiograms Circulation, June 1, 2004; 109(21): 2518 - 2523. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Heitzer, I. Ollmann, K. Koke, T. Meinertz, and T. Munzel Platelet Glycoprotein IIb/IIIa Receptor Blockade Improves Vascular Nitric Oxide Bioavailability in Patients With Coronary Artery Disease Circulation, August 5, 2003; 108(5): 536 - 541. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. D. O'Kane, L. R. Queen, Y. Ji, V. Reebye, P. Stratton, G. Jackson, and A. Ferro Aspirin modifies nitric oxide synthase activity in platelets: effects of acute versus chronic aspirin treatment Cardiovasc Res, July 1, 2003; 59(1): 152 - 159. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Cominacini, A. Fratta Pasini, U. Garbin, A. Pastorino, A. Rigoni, C. Nava, A. Davoli, V. Lo Cascio, and T. Sawamura The platelet-endothelium interaction mediated by lectin-like oxidized low-density lipoprotein receptor-1 reduces the intracellular concentration of nitric oxide in endothelial cells J. Am. Coll. Cardiol., February 5, 2003; 41(3): 499 - 507. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Browne, D. Meeking, K. Shaw, and M. Cummings Review: Endothelial dysfunction and pre-symptomatic atherosclerosis in type 1 diabetes -- pathogenesis and identification The British Journal of Diabetes & Vascular Disease, January 1, 2003; 3(1): 27 - 34. [Abstract] [PDF]
|
|
|
|
|
|
J. P. J. Halcox, K. R. A. Nour, G. Zalos, R. Mincemoyer, M. A. Waclawiw, C. E. Rivera, G. Willie, S. Ellahham, and A. A. Quyyumi The effect of sildenafil on human vascular function, platelet activation, and myocardial ischemia J. Am. Coll. Cardiol., October 2, 2002; 40(7): 1232 - 1240. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. P.J. Halcox, W. H. Schenke, G. Zalos, R. Mincemoyer, A. Prasad, M. A. Waclawiw, K. R.A. Nour, and A. A. Quyyumi Prognostic Value of Coronary Vascular Endothelial Dysfunction Circulation, August 6, 2002; 106(6): 653 - 658. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Tousoulis, C. Antoniades, C. Tentolouris, G. Goumas, C. Stefanadis, and P. Toutouzas L-Arginine in cardiovascular disease: dream or reality? Vascular Medicine, August 1, 2002; 7(3): 203 - 211. [Abstract] [PDF]
|
|
|
|
|
|
S. Verma, S. R. Raj, L. Shewchuk, K. J. Mather, and T. J. Anderson Cyclooxygenase-2 Blockade Does Not Impair Endothelial Vasodilator Function in Healthy Volunteers: Randomized Evaluation of Rofecoxib Versus Naproxen on Endothelium-Dependent Vasodilatation Circulation, December 11, 2001; 104(24): 2879 - 2882. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. P. Andrews, M. Husain, N. Dakak, and A. A. Quyyumi Platelet inhibitory effect of nitric oxide in the human coronary circulation: impact of endothelial dysfunction J. Am. Coll. Cardiol., February 1, 2001; 37(2): 510 - 516. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. M. Oomen, M. J. van Erk, E. J. M. Feskens, F. J. Kok, and D. Kromhout Arginine Intake and Risk of Coronary Heart Disease Mortality in Elderly Men Arterioscler Thromb Vasc Biol, September 1, 2000; 20(9): 2134 - 2139. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. R. Queen, B. Xu, K. Horinouchi, I. Fisher, and A. Ferro {beta}2-Adrenoceptors Activate Nitric Oxide Synthase in Human Platelets Circ. Res., July 7, 2000; 87(1): 39 - 44. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. G. Benditt, G. J. Fahy, K. G. Lurie, S. Sakaguchi, W. Fabian, and N. Samniah Pharmacotherapy of Neurally Mediated Syncope Circulation, September 14, 1999; 100(11): 1242 - 1248. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. J. Anderson Assessment and treatment of endothelial dysfunction in humans J. Am. Coll. Cardiol., September 1, 1999; 34(3): 631 - 638. [Full Text] [PDF]
|
|
|
|
|
|
H. Drexler Nitric oxide and coronary endothelial dysfunction in humans Cardiovasc Res, August 15, 1999; 43(3): 572 - 579. [Full Text] [PDF]
|
|
|
|
|
|
C. A. E. O'Blenes, C. Kinnear, and M. Rabinovitch Tumor Necrosis Factor-{alpha} Induces Fibronectin Synthesis in Coronary Artery Smooth Muscle Cells by a Nitric Oxide-Dependent Posttranscriptional Mechanism Circ. Res., July 6, 2001; 89(1): 26 - 32. [Abstract] [Full Text] [PDF]
|
|